Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
"Novavax" Q2 2026 Earnings Call - Sanofi Milestones Extend Cash Runway to 2029 as Matrix-M Platform Gains Traction in Oncology
Novavax is shedding its pandemic-era weight and rewriting its balance sheet through a disciplined pivot to a lean, partner-funded model. Second-quarter revenue came in at $57 million, but the structur...
- Novavax reported Q2 2026 total revenue of $57 million, comprising $19 million in product sales (up 76% year-over-year) and $36 million from Sanofi R&D reimbursements and amortization.
- The company raised its 2026 adjusted revenue guidance to $235 million to $275 million, with a midpoint of $255 million, citing stronger Matrix-M demand and partner royalties.
- Sanofi is advancing a combination COVID-19 and influenza vaccine, with regulators in advanced discussions for a Phase III trial that would trigger a $125 million milestone for Novavax.
- +7 more takeaways
Summit Hotel Properties Q2 2026 Earnings Call - Full-Year Guidance Raised as Urban Recovery and Channel Shift Drive Margin Expansion
Summit Hotel Properties delivered a quarter defined by pricing power and structural improvement, upgrading full-year guidance across RevPAR, EBITDAre, and FFO per share. Pro forma RevPAR climbed 5% ye...
- Summit Hotel Properties upgraded full-year guidance across RevPAR, EBITDAre, and FFO per share, reflecting a demand inflection that began in March and carried through July.
- Pro forma RevPAR climbed 5% year-over-year, entirely rate-driven with a 7.1% ADR increase, while hotel EBITDA expanded 7.8% and delivered nearly 90 basis points of margin accretion.
- The urban portfolio, representing half of total rooms and EBITDA, led the acceleration with a 9% ADR jump, 8% RevPAR growth, and 12% EBITDA expansion, anchored by corporate transient and group recovery.
- +9 more takeaways
BlackSky Technology Q2 2026 Earnings Call - Gen-3 Scaling Unlocks $100M Subscription Run Rate and 50% Revenue Growth
BlackSky Technology delivered a quarter defined by execution and scale. Revenue climbed 50 percent year-over-year to $33.3 million, propelled by record space-based intelligence and AI services that cr...
- Q2 revenue surged 50 percent year-over-year to $33.3 million, driven by a record $24.5 million in space-based intelligence and AI services.
- The company crossed a critical threshold by hitting a $100 million annual run rate for its high-margin imagery and AI subscription business.
- International subscription revenue jumped 150 percent year-over-year, with multi-year international contracts now representing over 80 percent of the funded backlog.
- +7 more takeaways
Ironwood Pharmaceuticals
Ironwood is proving that a mature franchise can still print cash. LINZESS delivered $282.3 million in second-quarter U.S. net sales, a 14% jump fueled by mid-single-digit prescription growth and a str...
- LINZESS reported $282.3 million in Q2 U.S. net sales, marking a 14% year-over-year increase driven by prescription volume growth and improved net pricing.
- Full-year 2026 LINZESS U.S. net sales guidance was raised to $1.15 billion to $1.2 billion, reflecting a projected >30% year-over-year increase and the product's return to blockbuster status.
- Prescription demand growth stabilized at 4% in Q2 and 5% year-to-date, with leadership upgrading the full-year demand forecast to mid-single digits after successfully mitigating Medicaid access concerns.
- +7 more takeaways
Americold Realty Trust Q2 2026 Earnings Call - Raised Full-Year AFFO Guidance Offcuts EQT Dilution as Occupancy Stabilizes
Americold Realty Trust did not wait for a demand inflection to deliver results. Second-quarter AFFO per share landed at $0.35, extending a four-quarter streak of meeting or beating consensus. Physical...
- Q2 AFFO per share reached $0.35, marking the fourth consecutive quarter of meeting or exceeding analyst consensus.
- Physical occupancy surged over 200 basis points sequentially and nearly 300 basis points year-over-year, fueled by record new business wins and the operational exit of smaller competitors.
- Economic occupancy turned positive year-over-year, narrowing the gap between physical and economic occupancy to 860 basis points.
- +7 more takeaways
"Arbe Robotics" Q2 2026 Earnings Call - Revenue Doubles as Defense Pivot and Cost Cuts Extend Cash Runway
Arbe Robotics just proved it can survive the transition from a niche automotive supplier to a diversified sensor vendor. Q2 revenue doubled to $0.7 million, gross loss compressed to breakeven, and ope...
- Q2 2026 revenue doubled to $0.7 million, marking the third consecutive quarter of growth.
- Gross loss narrowed to breakeven, reflecting improved unit economics on direct system sales.
- Operating expenses fell 13% to $9.8 million, driven by headcount reductions and lower share-based compensation.
- +8 more takeaways
"CACI International" Q4 and Fiscal Year 2026 Earnings Call - Margin Expansion and Free Cash Flow Surge Outpace Federal Budget Uncertainty
CACI International closed fiscal 2026 with a performance that underscores a deliberate pivot from traditional government services to a software-defined technology franchise. Revenue reached $9.6 billi...
- FY26 revenue reached $9.6 billion, up 10.9 percent year-over-year, with Q4 revenue of $2.7 billion and 11.6 percent organic growth.
- EBITDA margins expanded to 12.3 percent for the full year and 13.0 percent in Q4, driven by a higher mix of technology contracts and disciplined execution.
- Free cash flow surged to $735 million in FY26, marking a 68 percent increase per share, with FY27 guidance setting a floor at $900 million.
- +8 more takeaways
"Orion" Q2 2026 Earnings Call - Working Capital Discipline Offsets Feedstock Surge, Lifting Free Cash Flow
Orion’s second quarter reads like a study in operational triage. Adjusted EBITDA climbed 26% sequentially to $58 million, largely because the company stopped bleeding cash to volatile oil prices. Mana...
- Q2 Adjusted EBITDA reached $58 million, up 26% sequentially, though down 15% year-over-year.
- Specialty Segment Adjusted EBITDA surged 96% year-over-year to $39 million, driven by 5% volume growth, proactive pricing, and favorable product mix.
- Rubber Segment Adjusted EBITDA declined 61% year-over-year to $19 million, pressured by lower 2026 contractual pricing and inventory absorption, but remained sequential flat.
- +7 more takeaways
MidCap Financial Investment Corporation Q2 2026 Earnings Call - Management Halts Buybacks and Pivots to Deleveraging Amid Concentrated Credit Losses
MidCap Financial Investment Corporation’s second quarter reads like a deliberate retreat. NAV fell 3.2 percent to $13.37 per share, not from a broad market sell-off, but from a $50.3 million portfolio...
- NAV declined 3.2% to $13.37 per share, driven by a $50.3 million portfolio loss ($0.61 per share).
- Credit pressure is highly concentrated. Five positions account for roughly 80% of the quarterly loss, with ChyronHego alone generating a $21.5 million markdown.
- New lending has intentionally stalled. MFIC committed just $5.8 million to existing borrowers while collecting $160 million in net repayments.
- +9 more takeaways
"Versant Media" Q2 2026 Earnings Call - Raised Guidance and Platform Pivot Offset Linear Declines
Versant Media is navigating the cable transition without the safety net of a parent studio. The second quarter showed the structural shift in motion. Linear distribution continues to bleed subscribers...
- Revenue contraction is slowing. Total revenue fell 4% to $1.64 billion, but advertising only dropped 0.6% versus a 13% decline a year ago, signaling a floor in ad market weakness.
- Management raised full-year guidance. Revenue outlook moved to $6.2 billion to $6.45 billion, and adjusted EBITDA guidance shifted to $1.9 billion to $2.05 billion, reflecting confidence in the standalone portfolio.
- Platforms are the growth engine. Digital revenue hit $225 million, up 9% excluding SportsEngine, with Fandango and GolfNow scaling transaction volumes and subscriptions.
- +7 more takeaways